These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10683672)

  • 21. Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen.
    van Rij RP; van Praag RM; Prins JM; Rientsma R; Jurriaans S; Lange JM; Schuitemaker H
    Antivir Ther; 2002 Mar; 7(1):37-41. PubMed ID: 12008786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].
    Qiu ZF; Li TS; Ruan GR; Han Y; Xie J; Zuo LY; Li YL; Wang AX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):386-90. PubMed ID: 16900640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular automata and its advances to drug therapy for HIV infection.
    Peer MA; Shah NA; Khan KA
    Indian J Exp Biol; 2004 Feb; 42(2):131-7. PubMed ID: 15282943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [HIV-1 quantitative dynamics in vivo: a review of mathematical models].
    Le Corfec E; Rouzioux C; Costagliola D
    Rev Epidemiol Sante Publique; 2000 Apr; 48(2):168-81. PubMed ID: 10804426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The study of long-term HIV dynamics using semi-parametric non-linear mixed-effects models.
    Wu H; Zhang JT
    Stat Med; 2002 Dec; 21(23):3655-75. PubMed ID: 12436462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When to initiate HIV therapy: a control theoretic approach.
    Jeffrey AM; Xia X; Craig IK
    IEEE Trans Biomed Eng; 2003 Nov; 50(11):1213-20. PubMed ID: 14619991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression.
    Snedecor SJ
    Bull Math Biol; 2005 Nov; 67(6):1315-32. PubMed ID: 16005505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters.
    Capiluppi B; Ciuffreda D; Quinzan GP; Sciandra M; Marroni M; Morandini B; Costigliola P; Guerra L; Di Pietro M; Fibbia GF; Visonà R; Cusini M; Bressi C; Tambussi G; Lazzarin A
    J Biol Regul Homeost Agents; 2000; 14(1):58-62. PubMed ID: 10763896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simulating closed- and open-loop voluntary movement: a nonlinear control-systems approach.
    Davidson PR; Jones RD; Andreae JH; Sirisena HR
    IEEE Trans Biomed Eng; 2002 Nov; 49(11):1242-52. PubMed ID: 12450354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reservoirs dog AIDS therapy.
    Smaglik P
    Nature; 2000 May; 405(6784):270-2. PubMed ID: 10830936
    [No Abstract]   [Full Text] [Related]  

  • 37. Qualitative reasoning for AIDS treatment.
    Giacomini M; Ruggiero C; Gaglio S
    J Clin Comput; 1994 Apr; 22(2-3):2-10. PubMed ID: 10146119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short and long period optimization of drug doses in the treatment of AIDS.
    Caetano MA; Yoneyama T
    An Acad Bras Cienc; 2002 Sep; 74(3):379-92. PubMed ID: 12378307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Present state of closed-loop drug delivery in anesthesia and intensive care.
    Schüttler J; Schwilden H
    Acta Anaesthesiol Belg; 1999; 50(4):187-91. PubMed ID: 10603993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching.
    Cardozo EF; Zurakowski R
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():116-9. PubMed ID: 22254264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.